Effect of Gene Polymorphisms on GLP-1 Receptor Agonists Response in Patients With T2DM

• Status: Recruiting
• Trial end date: 2022-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an prospective study to evaluate the effect of gene polymorphisms on therapeutic responses to glucagon like peptide-1 receptor agonist (GLP-1 RA) in patients with T2DM.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Affiliated Hospital of Xuzhou Medical University
• Treatments: Glucagon-Like Peptide 1

Criteria

Inclusion Criteria:

1. a diagnosis of T2DM；

2. a body mass index (BMI) of 20-35 kg/m2；

3. an HbA1c of 7.0%-12%, an age of 25-70 years；

4. required data available at baseline, 3 months, and 6 months after GLP-1 RA therapy.

Exclusion Criteria:

1. Patients with serious diseases such as acute myocardial infarction, cerebral vascular accident, trauma, kidney or liver diseases, severe gastrointestinal dysfunction, and history of pancreatitis；

2. patients receiving GLP-1 analogues, weight loss drugs, glucocorticoids, drugs affecting gastrointestinal peristalsis in the past 3 months；

3. those with missing data at the time points of baseline, 3 months, and 6 months after GLP-1 RA therapy.